Fulcrum Therapeutics to Participate in Upcoming September Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming healthcare conferences in September 2024. The company, which focuses on developing small molecules for genetically defined rare diseases, will be attending:

1. The Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, in Boston, MA.

2. The Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York, NY.

During these events, Fulcrum's management team will engage in a series of investor meetings, providing an opportunity to discuss the company's progress and future plans in the field of rare disease treatments.

08/27/2024 - 04:05 PM

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:

Wells Fargo Healthcare Conference
Wednesday, September 4, 2024
Boston, MA

Morgan Stanley 22^nd Annual Global Healthcare Conference
Friday, September 6, 2024
New York, NY

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

What conferences will Fulcrum Therapeutics (FULC) attend in September 2024?

Fulcrum Therapeutics will attend the Wells Fargo Healthcare Conference on September 4, 2024, in Boston, and the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, in New York.